" class="no-js "lang="en-US"> Leading Femtech Brand INNOVO Appoints New CFO - Pharmtech Focus
Friday, January 27, 2023

Leading Femtech Brand INNOVO Appoints New CFO

Today Atlantic Therapeutics, a Galway-based MedTech and Femtech innovator, is pleased to announce the appointment of Rob Cartwright as Chief Financial Officer (CFO), effective immediately. Reporting to Susan Trent, CEO of Atlantic Therapeutics, Mr. Cartwright will provide executive leadership for all finance, legal, accounting, financial reporting, audit, tax, and capital planning functions.

Mr. Cartwright is a highly experienced, growth-oriented CFO, with over 23 years of experience in technology, internet, media and travel companies. Prior to joining Atlantic Therapeutics, Mr. Cartwright held leadership roles at MedMinder, Smart Destinations, Leisure Pass Group and Switchboard.com. He has been intimately involved in equity and debt financings as well as strategic exits, mergers, and acquisitions. Most recently, Mr. Cartwright was the CFO of Medminder, the leading fully integrated, end-to-end pharmacy, medication adherence and connected care solution for elderly and polypharmacy patients. Mr. Cartwright received an MBA in Finance from Bentley University, and has a Bachelor’s Degree in Accounting from Providence College.

“We are delighted with the appointment of Rob as CFO. Rob’s wealth of experience and track-record across several sectors will be a hugely valuable asset for the business as we continue to accelerate our rapid growth trajectory,” said Susan Trent, CEO of Atlantic Therapeutics. “Rob joins a strong team that have delivered phenomenal results. We are seeing strong market traction in the US, with sales growth of over 300% in 2021, and significant opportunities to bring the unique INNOVO innovation to new markets worldwide. We are at an inflection point for the brand, and together with all the Atlantic Therapeutics team I am excited to work with Rob on realising the enormous potential of INNOVO.”

Mr. Cartwright commented, “I am thrilled to be joining the Atlantic Therapeutics team at such an exciting time in their journey. I look forward to working with the Atlantic Therapeutics team to fulfil our mission of becoming the leading DTC brand for the treatment of stress urinary incontinence.”

People In This Post

Companies In This Post

  1. Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome Read more
  2. Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO Chews for Dogs Read more
  3. Sharecare Launches VR Program to Improve Well-being of American Workforce Read more
  4. Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer Read more
  5. Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment Read more